Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Molecular Weight | 516.7 g/mol |
---|---|
Molecular Formula | C25H36N6O4S |
XLogP3 | 3 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 11 |
Exact Mass | 516.25187482 g/mol |
Monoisotopic Mass | 516.25187482 g/mol |
Topological Polar Surface Area | 126 A^2 |
Heavy Atom Count | 36 |
Formal Charge | 0 |
Complexity | 894 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Details:
The proceeds will be used to support the ongoing global Phase 3 FUEL-2 trial of MZ101 (udenafil) for patients with Fontan circulation.
Lead Product(s): Udenafil,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Midas-Meritz
Deal Size: $20.0 million Upfront Cash: Undisclosed
Deal Type: Financing June 13, 2025
Lead Product(s) : Udenafil,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Midas-Meritz
Deal Size : $20.0 million
Deal Type : Financing
Mezzion Raises $20M to Advance Udenafil Phase 3 for Fontan Patients
Details : The proceeds will be used to support the ongoing global Phase 3 FUEL-2 trial of MZ101 (udenafil) for patients with Fontan circulation.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 13, 2025
Details:
Udenafil is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Heart Defects, Congenital.
Lead Product(s): Udenafil,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 26, 2023
Lead Product(s) : Udenafil,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Fontan Udenafil Exercise Longitudinal Assessment Trial - 2
Details : Udenafil is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Heart Defects, Congenital.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 26, 2023
Details:
The financing will fund FUEL-2, Mezzion's confirmatory phase 3 trial, along with future commercialization and regulatory submissions in other countries including Europe. Mezzion is looking to market JURVIGO® (udenafil), a highly selective, unique and potent PDE-5 inhibitor.
Lead Product(s): Udenafil,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Jurvigo
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: BRV Capital Management
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Financing April 25, 2023
Lead Product(s) : Udenafil,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : BRV Capital Management
Deal Size : $40.0 million
Deal Type : Financing
Details : The financing will fund FUEL-2, Mezzion's confirmatory phase 3 trial, along with future commercialization and regulatory submissions in other countries including Europe. Mezzion is looking to market JURVIGO® (udenafil), a highly selective, unique and po...
Product Name : Jurvigo
Product Type : Miscellaneous
Upfront Cash : Undisclosed
April 25, 2023
Details:
MZ101 (udenafil) is a phosphodiesterase type 5 inhibitor, improves measures of exercise performance at the ventilatory anaerobic threshold in individuals with fontan physiology.
Lead Product(s): Udenafil,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Jurvigo
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 21, 2023
Lead Product(s) : Udenafil,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MZ101 (udenafil) is a phosphodiesterase type 5 inhibitor, improves measures of exercise performance at the ventilatory anaerobic threshold in individuals with fontan physiology.
Product Name : Jurvigo
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 21, 2023
Details:
Mezzion sought clarity on the critical elements of an additional clinical trial that may be needed to complete the NDA submission for Udenafil for Single Ventricle Heart Disease.
Lead Product(s): Udenafil,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Jurvigo
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 31, 2022
Lead Product(s) : Udenafil,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Mezzion sought clarity on the critical elements of an additional clinical trial that may be needed to complete the NDA submission for Udenafil for Single Ventricle Heart Disease.
Product Name : Jurvigo
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 31, 2022
Details:
The FDA had previously granted Mezzion's request to designate udenafil for treatment of single ventricle congenital heart disease as a drug for a Rare Pediatric Disease.
Lead Product(s): Udenafil,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Jurvigo
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 25, 2021
Lead Product(s) : Udenafil,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The FDA had previously granted Mezzion's request to designate udenafil for treatment of single ventricle congenital heart disease as a drug for a Rare Pediatric Disease.
Product Name : Jurvigo
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 25, 2021
Details:
The NDA submission, which totals nearly 100,000 pages, is supported by data from more than 700 documents including more than 200 studies that Mezzion has completed during the last 2 decades since its founding in 2002.
Lead Product(s): Udenafil,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Jurvigo
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 30, 2020
Lead Product(s) : Udenafil,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Mezzion Announces Submission of NDA for its Orphan Drug Udenafil
Details : The NDA submission, which totals nearly 100,000 pages, is supported by data from more than 700 documents including more than 200 studies that Mezzion has completed during the last 2 decades since its founding in 2002.
Product Name : Jurvigo
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 30, 2020
Details:
Subjects on udenafil therapy showed a statistically significant improvement in ventricular performance as measured by MPI as compared to subjects taking placebo over the same time period.
Lead Product(s): Udenafil,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Jurvigo
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 18, 2020
Lead Product(s) : Udenafil,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Subjects on udenafil therapy showed a statistically significant improvement in ventricular performance as measured by MPI as compared to subjects taking placebo over the same time period.
Product Name : Jurvigo
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 18, 2020
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Tablet
Dosage Strength : 200MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Tablet
Dosage Strength : 200MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Packaging :
Regulatory Info :
Dosage : Tablet
Dosage Strength : 200MG
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Market Place
Reply
25 Jun 2020
Reply
11 Sep 2018
Reply
09 Aug 2018
Reply
25 Jun 2020
ABOUT THIS PAGE
68
PharmaCompass offers a list of Udenafil API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Udenafil manufacturer or Udenafil supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Udenafil manufacturer or Udenafil supplier.
PharmaCompass also assists you with knowing the Udenafil API Price utilized in the formulation of products. Udenafil API Price is not always fixed or binding as the Udenafil Price is obtained through a variety of data sources. The Udenafil Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Udenafil manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Udenafil, including repackagers and relabelers. The FDA regulates Udenafil manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Udenafil API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Udenafil manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Udenafil supplier is an individual or a company that provides Udenafil active pharmaceutical ingredient (API) or Udenafil finished formulations upon request. The Udenafil suppliers may include Udenafil API manufacturers, exporters, distributors and traders.
click here to find a list of Udenafil suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Udenafil Drug Master File in Korea (Udenafil KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Udenafil. The MFDS reviews the Udenafil KDMF as part of the drug registration process and uses the information provided in the Udenafil KDMF to evaluate the safety and efficacy of the drug.
After submitting a Udenafil KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Udenafil API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Udenafil suppliers with KDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Udenafil as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Udenafil API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Udenafil as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Udenafil and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Udenafil NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Udenafil suppliers with NDC on PharmaCompass.
Udenafil Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Udenafil GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Udenafil GMP manufacturer or Udenafil GMP API supplier for your needs.
A Udenafil CoA (Certificate of Analysis) is a formal document that attests to Udenafil's compliance with Udenafil specifications and serves as a tool for batch-level quality control.
Udenafil CoA mostly includes findings from lab analyses of a specific batch. For each Udenafil CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Udenafil may be tested according to a variety of international standards, such as European Pharmacopoeia (Udenafil EP), Udenafil JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Udenafil USP).